These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 24239359)

  • 1. Distinct and overlapping sarcoma subtypes initiated from muscle stem and progenitor cells.
    Blum JM; Añó L; Li Z; Van Mater D; Bennett BD; Sachdeva M; Lagutina I; Zhang M; Mito JK; Dodd LG; Cardona DM; Dodd RD; Williams N; Ma Y; Lepper C; Linardic CM; Mukherjee S; Grosveld GC; Fan CM; Kirsch DG
    Cell Rep; 2013 Nov; 5(4):933-40. PubMed ID: 24239359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in Fusion Negative Rhabdomyosarcoma.
    Pomella S; Sreenivas P; Gryder BE; Wang L; Milewski D; Cassandri M; Baxi K; Hensch NR; Carcarino E; Song Y; Chou HC; Yohe ME; Stanton BZ; Amadio B; Caruana I; De Stefanis C; De Vito R; Locatelli F; Chen Y; Chen EY; Houghton P; Khan J; Rota R; Ignatius MS
    Nat Commun; 2021 Jan; 12(1):192. PubMed ID: 33420019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SIX1 reprograms myogenic transcription factors to maintain the rhabdomyosarcoma undifferentiated state.
    Hsu JY; Danis EP; Nance S; O'Brien JH; Gustafson AL; Wessells VM; Goodspeed AE; Talbot JC; Amacher SL; Jedlicka P; Black JC; Costello JC; Durbin AD; Artinger KB; Ford HL
    Cell Rep; 2022 Feb; 38(5):110323. PubMed ID: 35108532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression and Differentiation of Alveolar Rhabdomyosarcoma Is Regulated by PAX7 Transcription Factor-Significance of Tumor Subclones.
    Skrzypek K; Adamek G; Kot M; Badyra B; Majka M
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic essentiality between PTEN and core dependency factor PAX7 dictates rhabdomyosarcoma identity.
    Langdon CG; Gadek KE; Garcia MR; Evans MK; Reed KB; Bush M; Hanna JA; Drummond CJ; Maguire MC; Leavey PJ; Finkelstein D; Jin H; Schreiner PA; Rehg JE; Hatley ME
    Nat Commun; 2021 Sep; 12(1):5520. PubMed ID: 34535684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of p16/Ink4a drives high frequency of rhabdomyosarcoma in a rat model of Duchenne muscular dystrophy.
    Teramoto N; Ikeda M; Sugihara H; Shiga T; Matsuwaki T; Nishihara M; Uchida K; Yamanouchi K
    J Vet Med Sci; 2021 Sep; 83(9):1416-1424. PubMed ID: 34334511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TWIST2-mediated chromatin remodeling promotes fusion-negative rhabdomyosarcoma.
    Shah AM; Guo L; Morales MG; Jaichander P; Chen K; Huang H; Cano Hernandez K; Xu L; Bassel-Duby R; Olson EN; Liu N
    Sci Adv; 2023 Apr; 9(17):eade8184. PubMed ID: 37115930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma.
    Doyle B; Morton JP; Delaney DW; Ridgway RA; Wilkins JA; Sansom OJ
    J Pathol; 2010 Oct; 222(2):129-37. PubMed ID: 20662002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment of a novel experimental system using single cell-derived pleomorphic rhabdomyosarcoma cell lines expressing K-RasG12V and deficient in p53.
    Saito H; Suzuki N
    Exp Anim; 2023 Nov; 72(4):446-453. PubMed ID: 37081671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining the Extracellular Matrix of Rhabdomyosarcoma.
    Lian X; Bond JS; Bharathy N; Boudko SP; Pokidysheva E; Shern JF; Lathara M; Sasaki T; Settelmeyer T; Cleary MM; Bajwa A; Srinivasa G; Hartley CP; Bächinger HP; Mansoor A; Gultekin SH; Berlow NE; Keller C
    Front Oncol; 2021; 11():601957. PubMed ID: 33708626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mouse genetic background influences whether
    Brandt LP; Albers J; Hejhal T; Pfundstein S; Gonçalves AF; Catalano A; Wild PJ; Frew IJ
    Oncotarget; 2018 Apr; 9(28):19753-19766. PubMed ID: 29731980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developmental Heterogeneity of Rhabdomyosarcoma.
    Stevens BT; Hatley ME
    Cold Spring Harb Perspect Med; 2024 May; ():. PubMed ID: 38772705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methods to generate genetically engineered mouse models of soft tissue sarcoma.
    Dodd RD; Añó L; Blum JM; Li Z; Van Mater D; Kirsch DG
    Methods Mol Biol; 2015; 1267():283-95. PubMed ID: 25636474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes.
    Sachdeva M; Mito JK; Lee CL; Zhang M; Li Z; Dodd RD; Cason D; Luo L; Ma Y; Van Mater D; Gladdy R; Lev DC; Cardona DM; Kirsch DG
    J Clin Invest; 2014 Oct; 124(10):4305-19. PubMed ID: 25180607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New insights into signalling-pathway alterations in rhabdomyosarcoma.
    Zhu B; Davie JK
    Br J Cancer; 2015 Jan; 112(2):227-31. PubMed ID: 25211658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation.
    Tremblay AM; Missiaglia E; Galli GG; Hettmer S; Urcia R; Carrara M; Judson RN; Thway K; Nadal G; Selfe JL; Murray G; Calogero RA; De Bari C; Zammit PS; Delorenzi M; Wagers AJ; Shipley J; Wackerhage H; Camargo FD
    Cancer Cell; 2014 Aug; 26(2):273-87. PubMed ID: 25087979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute tissue injury activates satellite cells and promotes sarcoma formation via the HGF/c-MET signaling pathway.
    Van Mater D; Añó L; Blum JM; Webster MT; Huang W; Williams N; Ma Y; Cardona DM; Fan CM; Kirsch DG
    Cancer Res; 2015 Feb; 75(3):605-14. PubMed ID: 25503558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-throughput flow cytometry screening reveals a role for junctional adhesion molecule a as a cancer stem cell maintenance factor.
    Lathia JD; Li M; Sinyuk M; Alvarado AG; Flavahan WA; Stoltz K; Rosager AM; Hale J; Hitomi M; Gallagher J; Wu Q; Martin J; Vidal JG; Nakano I; Dahlrot RH; Hansen S; McLendon RE; Sloan AE; Bao S; Hjelmeland AB; Carson CT; Naik UP; Kristensen B; Rich JN
    Cell Rep; 2014 Jan; 6(1):117-29. PubMed ID: 24373972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation and comparison of CRISPR-Cas9 and Cre-mediated genetically engineered mouse models of sarcoma.
    Huang J; Chen M; Whitley MJ; Kuo HC; Xu ES; Walens A; Mowery YM; Van Mater D; Eward WC; Cardona DM; Luo L; Ma Y; Lopez OM; Nelson CE; Robinson-Hamm JN; Reddy A; Dave SS; Gersbach CA; Dodd RD; Kirsch DG
    Nat Commun; 2017 Jul; 8():15999. PubMed ID: 28691711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting glutamine metabolism improves sarcoma response to radiation therapy in vivo.
    Patel R; Cooper DE; Kadakia KT; Allen A; Duan L; Luo L; Williams NT; Liu X; Locasale JW; Kirsch DG
    Commun Biol; 2024 May; 7(1):608. PubMed ID: 38769385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.